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Abstract
Purpose: To assess treatment toxicity and patients’ survival/quality of life (QoL) after volumetric modulated arc
therapy (VMAT) with simultaneous in-field boost (SIB) for cancer patients with 1 - 4 brain metastases (BM) treated
with or without surgery.
Methods and Materials: Between March and December 2010, 29 BM patients (total volume BM, < 40 cm
3) aged
< 80 years, KPS ≥ 70, RPA < III were included in this prospective trial. Whole brain VMAT (30 Gy) and a SIB to the
BM (40 Gy) was delivered in 10 fraction. Mean age was 62.1 ± 8.5 years. Fifteen (51.7%) underwent surgery. KPS
and MMSE were prospectively assessed. A self-assessed questionnaire was used to assess the QoL (EORTC QLQ-C30
with -BN20 module).
Results: As of April 2011 and after a mean FU of 5.4 ± 2.8 months, 14 (48.3%) patients died. The 6-month overall
survival was 55.1%. Alopecia was only observed in 9 (31%) patients. In 3-month survivors, KPS was significantly (p =
0.01) decreased. MMSE score remained however stable (p = 0.33). Overall, QoL did decrease after VMAT. The mean
QLQ-C30 global health status (p = 0.72) and emotional functional (p = 0.91) scores were decreased (low QoL).
Physical (p = 0.05) and role functioning score (p = 0.01) were significantly worse and rapidly decreased during
treatment. The majority of BN20 domains and single items worsened 3 months after VMAT except headaches (p =
0.046) and bladder control (p = 0.26) which improved.
Conclusions: The delivery of 40 Gy in 10 fractions to 1 - 4 BM using VMAT was achieved with no significant
toxicity. QoL, performance status, but not MMSE, was however compromised 3 months after treatment in this
selected cohort of BM patients.
Introduction
Brain metastases (BMs) occur in 25 to 45% of all cancer
patients and represent thus a significant clinical problem
in cancer management [1]. Whole brain radiation therapy
(WBRT) with steroids is usually the primary treatment
option for patients with multiple BMs. Patients with 1 - 4
BMs are routinely treated with surgery and/or radiosur-
gery, with or without WBRT. After these treatments,
local and distant brain failure is however a clinical issue
and occurs in a substantial number of patients. Two pro-
spective phase III trial have shown a 1-year local and/or
brain failure rate of 30% - 100% [2,3].
Improvement of local control of BM may not necessa-
rily lead to improved survival but is of paramount impor-
tance to maintain neurological function and may be a
worthwhile objective, especially in subsets of patients
with a better prognosis. Treatment failure has been
s h o w nt oh a v ea ni m p a c to np a t i e n t ’s neurocognitive
function [4] and possibly quality of life (QoL) [5]. As
such, selected subgroups of patients (i.e. younger age,
good performance status, controlled primary tumor,
absence of extracranial disease and/or limited number of
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this strategy is historically controversial [7,8]. Any dose
escalation paradigm may translate however in increased
radiation-induced toxicity and may have a deleterious
effect on neurocognitive function and/or QoL. Two stu-
dies assessed the QoL in patients with primary brain
tumors and BMs [9,10], but no study has studied pro-
spectively this end-point specifically for BM’sp a t i e n t s
treated with a dose-escalation paradigm. Consequently,
we embarked in a prospective study assessing the toxi-
city, neurocognitive function and QoL of good prognostic
patients with 1 - 4 BM treated with a dose escalation
strategy using a volumetric modulated arc therapy tech-
nique (VMAT).
Patients and methods
Patients and Treatment characteristics
From March 2010 to December 2010, 29 patients with
previously untreated brain metastasis were included into
an institutional prospective protocol of WBRT with SIB to
single or multiple BMs. Patient eligibility for this trial was
as follows: histologically proven cancer; brain MRI consis-
tent with BM(s); 1 to 4 BMs; age < 80 years; Karnofsky
performance status (KPS) ≥ 70; RPA < III; total volume of
BM ≤ 40 ml and no previous cranial RT. The presence of
extracranial disease was allowed. Patients were allowed to
undergo craniotomy. Quality-of-life (QoL) was evaluated
prospectively using the QLQ-C30 and -BN20 instruments
developed by the European Organization for Research and
Treatment of Cancer (EORTC). The primary end-point of
this study was QoL. The secondary endpoints were toxi-
city, overall survival (OS) and brain progression-free survi-
val (PFS). The characteristics of the patients are detailed in
Table 1.
The gross tumor volume (GTV) was defined as the BM
and/or the surgical resection cavity. The planning target
volume (PTV) was obtained by adding a 3 mm margin to
the GTV. In association with WBRT, a SIB was adminis-
tered to all brain lesions. A composite VMAT plan was
generated for all patients, consisting of WBRT (30 Gy in
10 fractions) with a SIB of 10 Gy in 10 fractions to the
PTVs. The cumulative dose delivered to the BM(s) was
thus 40 Gy in 10 fractions. The treatment plans were gen-
erated using a volumetric modulated arc therapy (VMAT)
technique, all computed on the Varian Eclipse treatment
planning system with 6 MV photon beams from a Varian
Clinac equipped with a Millennium Multileaf Collimator
(MLC; Novalis Tx, BrainLab, Feldkirchen, Germany) with
120 leaves. Plans were optimized selecting a maximum
dose rate of 600 MU/min. Two modulated arcs were used
for all patients. Mean UM delivered was 671 ± 142.
Patients were treated using a thermoplastic immobili-
zation mask used during simulation, with positioning
determined by co-registration of the simulation kV CT
scan with a MVCT scan acquired on the treatment unit.
Quality-of-life questionnaires and administration
QoL in this study was assessed with the EORTC QLQ-
C30 (version 3.0) and-QLQ-BN20. The self-administered
QLQ-C30 is the EORTC core QoL questionnaire that
addresses a range of functional outcomes and symptoms
relevant to a wide range of cancer populations [11]. This
30-item questionnaire is composed of both multi-item
scales and single-item measures. It is composed of a glo-
bal health status (GHS) scale (2 items), functional scales
(15 items) and symptom scales/items (13 items). Func-
tional scales consist of physical (PF), role (RF), emotional
(EF), cognitive and social functioning scales. Each item is
scored from 1 to 4 (’’not at all’’:1 ;‘’a little’’:2 ;‘’quite a
Table 1 Patient’s characteristics (n = 29)
n%
Gender
Male 16 55.2
Female 13 44.8
Age (Years)
Median 62.3 (range, 42-78.3)
Mean 62.1 ± 8.5
RPA
I 6 20.7
II 23 79.3
GPA
0 - 1 3 10.3
1.5 - 2.5 21 72.5
3 3 10.3
3.5 - 4 2 6.9
Primary Tumor
Lung 22 76.0
Breast 3 10.3
Melanoma 1 3.4
Other 3 10.3
Number of BM
1 13 44.8
2 - 3 9 30.1
4 7 24.1
Surgery 15 51.7
Concomitant chemotherapy 10 34.5
Abbreviations : RPA, Recursive Partitioning Analysis; GPA, Graded Prognosis
Assesment; BM, Brain Metastasis.
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from 1 (‘‘very poor’’)t o7( ‘‘excellent’’). Raw scores (RS)
were obtained by calculating the average of all item com-
ponents. Item range is the difference between the maxi-
mum and minimum response to an individual item. The
core calculation is detailed in the Appendix. A higher
score for the GHS and functional scales represent thus a
higher QoL and high level of functioning, respectively.
C o n v e r s e l y ,ah i g hs c o r ef o ras y m p t o ms c a l er e p r e s e n t s
a high level of symptomatology.
The self-administered QoL questionnaire BN20 consists
of 4 multi-items scale that assesses: future uncertainty
(4 items), visual disorder (3 items), motor dysfunction
(3 items) and communication deficit (3 items) [12]. Addi-
tionally, symptoms are addressed by single items: head-
aches, hair loss, weakness of legs and bladder control. The
scoring algorithm for the scales is similar to the scoring of
the EORTC-C30 questionnaire. RS are computed and line-
arly transformed to a 0 - 100 scale. For the scales and
items, a higher score represents worse QoL. Details of the
in-field testing of the BN20 in a multi-national and multi-
lingual setting have been published previously [13].
The QoL assessment took place during the first con-
sultation in the radiation oncology department, during
VMAT (week 1 & 2) and every 3 months after the end
of VMAT until tumor progression. All QLQ-C30 and
-BN20 scores were prospectively collected into an insti-
tutional electronic database.
Performance status and neurocognitive function
Performance status was assessed using the standard KPS
scale [14]. Neurocognitive function was assessed using
the MMSE dementia-scale [15], which has been shown
to be a survival prognosticator in BM patients [16]. The
baseline and follow-up evaluation of the KPS and
MMSE was performed by the same attending radiation
oncologist before the start of treatment, during and
after VMAT.
Radiation-induce toxicity
Alopecia was were classified according to the National Can-
cer Institute Common Terminology Criteria for Adverse
Events (CTCAE) v3.0 grading system http://ctep.cancer.
gov/search/search.asp?zoom_query = CTCAE&Action =
Go%3E, except for skin toxicity which was scored using the
Radiation Therapy Oncology Group (RTOG) scoring sys-
tem http://www.rtog.org/ResearchAssociates/AdverseEven-
tReporting/CooperativeGroupCommonToxicityCriteria.
aspx. Toxicity assessment was made during VMAT (week 1
& 2) and every 3 months after the end of VMAT.
Statistical analysis
OS and PFS were calculated using the Kaplan Meier
method [17]. Recorded events were death (all causes of
death included) and local and distant brain failure for
OS and PFS, respectively. Survival differences between
subgroups were evaluated using the log-rank test (p
value < 0.05 was considered statistically significant).
QoL results are presented as mean scores with standard
deviations and were compared between time points
using the Wilcoxon rank sum test and a p value < 0.05
was considered statistically significant. All analyses were
performed using the SPSS statistical package (SPSS 17.0,
Chicago, IL).
Results
Patients’ outcome and prognostic factors
After a mean FU of 5.4 ± 2.8 months, 14 (48.3%)
patients died. The 6-month OS was 55.1%. Patient
undergoing surgery survived significantly longer than
those not undergoing surgery: the estimated 6-month
OS was 72.0% vs. 33.5%, respectively (p = 0.035). Like-
wise, patients with good performance status lived signifi-
cantly longer. The estimated 6-month OS was 66.9%
and 37.5% for patients with a KPS of 90-100 and 70-80,
respectively (p = 0.025). Motor dysfunction (p = 0.11),
emotional functioning (EF; p = 0.25), role functioning
(RF; p = 0.27), future uncertainty (p = 0.35), global
health status (GHS; p = 0.38), MMSE (p = 0.40), visual
deficit (p = 0.59), number of BM (p = 0.64), age (p =
0.66), communication deficit (p = 0.79), gender (p =
0.80) and physical functioning (PF; p =0 . 8 5 )w e r eh o w -
ever not prognostic for OS in this study.
Overall, 6 treatment failures were observed. Three
(13.0%) patients presented with local failure but distant
brain control and another 3 (13.0%) presented with local
control but distant brain failure. The estimated 6-
months brain PFS was 77.9%. Overall, 23 (79.4%)
patients were controlled locally and distantly in the
brain. The majority (n = 17 out of 23 tumour progres-
sion; 74.0%) presented with progressive extra-cranial
systemic disease. Toxicity was minimal. No radiation-
induced erythema was observed. Grade CTCAE 1 and 2
alopecia was only observed in 9 (31.0%) patients.
QoL and neurocognitive function
MMSE, KPS and self-assessed QoL were compared dur-
ing VMAT. Nineteen (65.5%) patients completed all
questionnaires before and during VMAT (week 1 and
2). The reasons for not completing the questionnaires in
the other 10 (34.5%) patients were as follow: accidental
destruction of the QoL questionnaires by the adminis-
trative team in 5 patients, deterioration of cognitive
function or performance status preventing completing
of the questionnaires in 2 patients, non compliance in
questionnaire administration by physicians in 2 patients
and patient refusal in 1 patients. During VMAT, the
performance status decreased although not significantly
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and 85.3 ± 18.1, respectively (p > 0.1). MMSE signifi-
cantly improved however during VMAT. Mean MMSE
scores were 27.1 ± 2.7 and 28.1 ± 2.5 (p = 0.04). During
VMAT, GHS remained stable (Figure 1; Table 2). For
the C30 functional scale, a statistical trend was observed
f o rd e c r e a s i n gP Fd u r i n gV M A T( F i g u r e1 ;T a b l e2 ) .E F
remained fairly stable during VMAT (Figure 1; Table 2).
RF was however significantly decreased during VMAT
(Figure 1; Table 2). Table 2 details the domain’s and sin-
gle item’s scores of the BN20 questionnaire during
VMAT. Headaches were significantly decreased during
VMAT. Mean headache-BN20 observed scores were
37.0 ± 41.0 and 18.5 ± 23.5 before and during VMAT,
respectively (p = 0.048; Table 2). A statistical trend was
observed for future uncertainty, which decreased during
VMAT (Table 2; p = 0.07). Communication deficit also
decreased during VMAT, although no statistical trend
was observed (Table 2; p = 0.13). Interestingly, hair loss
issues was reported less often during VMAT (Table 2;
p = 0.11).
MMSE, KPS and self-assessed QoL were also com-
pared for the time points before and 3 months after the
start of VMAT. Fourteen (77.8%) patients completed
questionnaires at both time points. The reason for not
completing the questionnaires in the other 4 (22.2%)
patients was death within 3 months after VMAT in all
patients. Among the patients completing the question-
naire, 4 (28.6%) presented with systemic progressive dis-
ease. Three brain failures (21.4%) were observed. At
3-months follow-up, patients had a significantly worse
performance status. Mean KPS scores were 92.1 ± 8.0
and 82.1 ± 15.8 before and after VMAT, respectively
(p = 0.01). MMSE score were however stable. Mean
MMSE scores were 27.3 ± 2.4 and 27.4 ± 4.2 before and
3 months after VMAT, respectively (p = 0.33). GHS
remained fairly stable (Figure 2; Table 3). For PF, a sta-
tistical trend was observed for decreasing values after
VMAT (Figure 2; Table 3). EF remained also stable after
VMAT (Figure 2; Table 3). RF was however significantly
decreased (Figure 2; Table 3).
Table 3 details the domain’s and single item’ss c o r e s
of the BN20 questionnaire. Except for headache and
bladder control scores, all other scores worsened 3
months after VMAT. As mentioned, headaches were
significantly decreased after VMAT. Mean headache-
BN20 observed scores were 33.3 ± 37.0 and 7.1 ± 14.2
before and 3 months after VMAT, respectively (p =
0.046; Table 3). Interestingly, hair loss was reported
more often 3 months after VMAT, although not signifi-
cantly so. Mean hair loss-BN20 observed scores were
14.3 ± 31.2 and 23.8 ± 30.5 before and 3 months after
VMAT, respectively (p = 0.48; Table 3).
MMSE, KPS and self-assessed QoL were also com-
pared for the time points before and 6 months after the
start of VMAT. Five (17.2%) patients completed ques-
tionnaires at both time points. All other patients with
complete C30 and BN20 data did not reach this time
point. In these patients, no local or distant brain failure
was observed. One patient presented with progressive
extra-cranial systemic disease. Mean KPS scores were
94.0 ± 5.5 and 90 ± 14.1 before and 6 months after
VMAT, respectively (p = 0.41). Mean MMSE scores
were 27.0 ± 2.4 and 27.8 ± 2.9 before and 6 months
after VMAT, respectively (p = 0.18). EORTC-C30 scores
remained stable (Table 4). Table 4 also details the
domain’s and single item’s scores of the BN20 question-
naire. All but communication deficit domains were non-
significantly worse at 6 months (Table 4).
Discussion
T ot h eb e s to fo u rk n o w l e d g e ,t h ep r e s e n ts t u d yi st h e
first series ever published on a prospective evaluation of
QoL in patients with BM, not including primary brain
tumors, treated with VMAT and dose escalation. The
efforts at developing new therapeutic strategies in BM
should not only focus on increasing survivorship but
should also assess their relative impact on QoL. Dose
escalation may be potentially neurotoxic and thus nega-
tively affect health-related QoL in these BM patients. As
such, we embarked in a careful prospective evaluation of
QoL in a pilot VMAT dose escalation protocol. Our
data suggests several comments. First, QoL assessment
was indeed difficult in this patient cohort, even though
 
 
 
 
 
 
*  
 
*p=0.05 
**p=0.02 
                                                                              *     ** 
During VMAT 
Figure 1 Self-assessed QoL (EORTC-C30) before and during
VMAT for Global Health Status, and physical, emotional and
role functioning.
Weber et al. Radiation Oncology 2011, 6:79
http://www.ro-journal.com/content/6/1/79
Page 4 of 8a dedicated physician was assigned to do the QoL
assessment. The difficulty in assessing QoL or neurocog-
nitive function in patients with BM has been reported
by other investigators [5,14]. Only one patient out of
two could be assessed at the 3 months post-VMAT time
point, as a result of decreasing performance status and/
or cognitive function, administrative issues or patient
refusal. Second, the overall QoL of these patients did
indeed decrease 3 months after VMAT as reported by
other authors [18](Table 3). In order to avoid any
potential bias originating from the death of patients
with poor-QoL, the comparison of QoL at the two time
points (i.e. baseline and at 3 months) was performed
using only data from patients completing questionnaires
at both time points [19]. Additionally, performance sta-
tus did also significantly decrease, but the neurocogni-
tive function, assessed with the MMSE, appeared to be
stable in this small cohort. Interestingly, the levels of
three EORTC-BN20 domains, namely visual disorder,
motor dysfunction and communication deficit, remained
stable at this time point, suggesting a possible associa-
tion between MMSE and these scores, as reported by
other authors [13]. Third, except for physical and role
functioning (Figure 1), the observed QoL did not sub-
stantially decrease during treatment. MMSE significantly
increased during treatment, possibly as a result of the
therapeutic effect of radiation. Although one third of
patients experienced alopecia, the EORTC-BN20 mean
score for this item was decreased (Table 2), suggesting
that there is not necessarily agreement between patient
and physician reports of symptoms or toxicity [20,21].
Some EORTC-BN20 domains were even improved dur-
ing VMAT (Table 2), with an observed statistical trend
for future uncertainty levels, which may reflect the effec-
tiveness of coping strategies. Finally, lower functional
and GHS scores in the EORTC-C30 questionnaire and
higher EORTC-BN20 domain’ss c o r e sw e r ea s s o c i a t e d
with decreased survival suggesting that these scores may
be relevant prognosticators for BMs [18]. Although no
statistical trend was observed, possibly as a result of
small numbers, all Kaplan-Meier curves were parallel to
Table 2 EORTC-C30 and -BN20 domain and single item’s scores before and during VMAT
QoL Pre-VMAT score ± SD Score during VMAT ± SD p value
C30
Global Health Status 62.5 ± 26.4 62.0 ± 21.4 0.92
Physical functioning 78.9 ± 22.9 65.1 ± 31.2 0.05
Emotional functioning 74.8 ± 20.1 74.3 ± 27.0 0.86
Role functioning 75.0 ± 21.6 55.5 ± 37.1 0.02
BN20 domains/items
Domains
Future uncertainty 30.8 ± 20.9 18.8 ± 23.5 0.07
Visual disorder 13.6 ± 20.7 13.3 ± 17.4 0.92
Motor dysfunction 22.5 ± 24.1 22.2 ± 26.9 0.64
Communication deficit 19.7 ± 28.1 13.6 ± 16.8 0.13
Single items
Headache 37.0 ± 41.0 18.5 ± 23.5 < 0.05
Hair loss 14.8 ± 30.7 3.7 ± 15.7 0.11
Weakness of legs 24.1 ± 29.8 25.9 ± 31.4 0.58
Bladder control 16.7 ± 30.8 14.8 ± 28.5 0.79
Abbreviations: QoL: Quality of life; SD, standard deviation.
AfterVMAT
* **
* p=0.05
**p=0.01
Figure 2 Self-assessed QoL (EORTC-C30) before and 3 months
after VMAT for Global Health Status, and physical, emotional
and role functioning.
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decreased survivorship (data not shown). Using tradi-
tional method of statistical analysis (i.e. Cox multivariate
model) controlled for major clinical prognostic factors,
some EORTC-C30 or -BN20 items, such as cognitive
function or GHS, have been significantly associated with
survival in two prospective trials [22,23], although these
results are controversial [9,24,25]. The mechanisms
underlying these potential associations are however
unclear. QoL scores may reflect the patient’sp h y s i c a l
and psychological state that may have a positive effect
on the overall disease process (i.e. higher QoL score are
a proxy for the patient’s health status that may have a
positive effect on the underlying disease). Alternatively
to this true causative relationship, these scores may
reveal the early perception and severity of the disease
more accurately than conventional prognostic indices
(i.e. lower QoL score reflect a worse underlying disease).
Table 3 EORTC-C30 and -BN20 domain and single item’s scores before and 3 months after VMAT
QoL Pre-VMAT scoren ± SD Score during VMAT ± SD p value
C30
Global Health Status 65.4 ± 22.8 60.1 ± 26.6 0.72
Physical functioning 81.4 ± 17.6 63.3 ± 29.8 0.05
Emotional functioning 77.7 ± 21.2 74.4 ± 26.2 0.91
Role functioning 72.6 ± 22.3 45.2 ± 37.8 0.01
BN20 domains/items
Domains
Future uncertainty 27.1 ± 20.7 27.4 ± 31.6 0.66
Visual disorder 12.7 ± 21.3 15.1 ± 21.2 0.25
Motor dysfunction 21.4 ± 24.8 22.2 ± 33.5 0.96
Communication deficit 23.0 ± 30.3 27.8 ± 29.5 0.55
Single items
Headache 33.3 ± 37.0 7.1 ± 14.2 < 0.05
Hair loss 14.3 ± 31.2 23.8 ± 30.5 0.48
Weakness of legs 21.4 ± 24.8 28.6 ± 34.2 0.39
Bladder control 21.4 ± 33.6 11.9 ± 24.8 0.26
Abbreviations: QoL: Quality of life; SD, standard deviation.
Table 4 EORTC-C30 and -BN20 domain and single item’s scores before and 6 months after VMAT
QoL Pre-VMAT score ± SD Score during VMAT ± SD p value
C30
Global Health Status 62.5 ± 26.4 68.8 ± 20.8 0.47
Physical functioning 78.9 ± 22.9.6 71.9 ± 26.0 0.72
Emotional functioning 74.8 ± 20.1 70.0 ± 41.5 0.89
Role functioning 75.0 ± 21.6 73.3 ± 41.8 0.72
BN20 domains/items
Domains
Future uncertainty 26.0 ± 23.5 30.0 ± 41.5 0.72
Visual disorder 15.5 ± 12.7 28.9 ± 36.5 0.41
Motor dysfunction 15.5 ± 16.8 24.4 ± 30.8 0.59
Communication deficit 22.2 ± 28.3 6.6 ± 6.1 0.29
Single items
Headache 26.7 ± 43.5 20.0 ± 29.8 0.99
Hair loss 13.3 ± 29.8 0.0 ± 0.0 0.32
Weakness of legs 20.0 ± 18.2 26.6 ± 27.9 0.66
Bladder control 0.0 ± 0.0 0.0 ± 0.0 1.00
Abbreviations: QoL: Quality of life; SD, standard deviation.
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the QoL parameters or the high variability in survival in
patients with identical QoL scores to name a few, have
been raised by the use of classical methods of statistical
computation [23]. Further research regarding the prog-
nostic value of health-related QoL is justified in the fra-
mework of future prospective trials.
We sought to investigate whether a hypofractionated
SIB approach for the treatment of patients with 1 - 4
BMs would be a safe alternative to WBRT with or with-
out radiosurgery. The observed toxicity was minimal.
Less than one third of patients had alopecia at the end
of treatment. These results may be in keeping with
recent phase I dose escalation studies reporting the toxi-
city in patients treated with WBRT and an SIB techni-
que [26,27]. In the US study, alopecia and skin reaction
were reported in 16% and 6% of patients, respectively
[26]. The reduction of the observed alopecia rates, when
compared to those observed with WBRT, may have an
impact on the patient’s QoL, as assessed by the
EORTC-BN20 questionnaire (Table 4).
The treatment of patients with BM can consist of best
supportive care, surgery or radiosurgery with or without
WBRT. We have included patients with one BM in our
treatment protocol as the modulation of the WBRT by a
VMAT approach may produce steeper radiation-dose
gradients than plans with conventional WBRT summed
with radiosurgery dose deposition [28]. For patients with
good- to intermediate-prognosis (i.e. RPA I - II), such as
those treated in our protocol, a multi-modality treatment
strategy is usually proposed with the aim of preventing
intracranial progression, preserving the neurologic func-
tion and possibly the overall QoL. In our study, local and
distant brain tumor control was achieved in a majority of
patients. Unfortunately, systemic extracranial progression
was observed in a majority (74.0%) of patients with a con-
sequential impact on survivorship. Interestingly, the esti-
mated 6-months OS was significantly increased (72% vs.
33.5%) when surgery was performed to patients with 1 -
4 BM. These results should be interpreted cautiously, as
they may be subject to uncontrolled patient selection
into different treatment groups (i.e. better KPS and RPA/
GPA scores for patients undergoing surgery). They are
however in line with several prospective studies confirm-
ing the importance of surgery in selected patients [29,30].
Although we did not perform a multivariate analysis as
the number of events relative to the potential parameters
was inappropriate, these data suggest that dose escalation
only with a SIB technique may not be the optimal treat-
ment for these good- to intermediate-prognosis patients.
There were several limitations of our study. First, the
small sample size of 29 patients limited the statistical
power to assess fully the QoL of BM patients treated
with VMAT and to detect associations between survival
and the EORTC-C30 and -BN20 parameters. Second,
the rate of completion of the questionnaires in these
severely ill patients, although identical to the compliance
rate reported in the literature, was suboptimal. High
compliance in questionnaire completion is difficult to
achieve in severely ill patients as their condition deterio-
rates over time. Third, as the number of brain progres-
sions was low, the impact of this event on patient’s QoL
at the 3 months time point was not assessable. This
being said, this study was a prospective study with speci-
fic QoL endpoints and the BM patient cohort studied
was homogeneous and represented a good- to inter-
mediate-prognosis population for whom the QoL is of
paramount importance.
In summary, the delivery of 40 Gy in 10 fractions
using a VMAT technique was achieved with no signifi-
cant toxicity. The majority of patients presented with
extracranial progressive disease. Surgery and perfor-
mance status were significant prognostic factors for sur-
vival. Although the QoL did not decrease significantly
during treatment, a decrease of several EORTC-C30 and
-BN20 parameters was observed at 3 months after
VMAT.
Additional material
Additional file 1: Appendix. Equations for functional scale, GHS and
symptom scales/items scores.
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